Impact of cessation of antiviral therapy at delivery on postpartum liver function in mothers with chronic hepatitis B virus infection
10.3760/cma.j.issn.1007-3418.2019.02.008
- VernacularTitle: 妊娠期抗病毒治疗的慢性乙型肝炎病毒感染孕妇分娩时停药对产后肝功能的影响
- Author:
Huijie GUO
1
;
Yunfei GAO
2
;
Huiyuan LIU
3
;
Haitang HE
4
;
Meiting HUANG
4
;
Danchun CAI
2
;
Dandan LIAO
2
;
Jinna LI
4
;
Xueru YIN
4
;
Zhihua LIU
4
;
Jing HU
1
,
5
Author Information
1. Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou 510515, China
2. Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
3. Department of Severe Liver Disease, Guangzhou Eighth People's Hospital, Guangzhou 510060, China
4. Institute of Hepatology and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
5. Department of Hospital Infection Management, Zhujiang Hospital, Southern Medical University, Guangzhou 510220, China
- Publication Type:Journal Article
- Keywords:
Hepatitis B virus;
Pregnancy;
Antiviral therapy;
Liver function
- From:
Chinese Journal of Hepatology
2019;27(2):112-117
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the impact of immediate cessation of antiviral therapy on postpartum liver function and the factors influencing postpartum abnormality in mothers with chronic hepatitis B virus infection.
Methods:A retrospective cohort study was conducted. One hundred eighty-eight pregnant women with HBV DNA level > 2×106 IU/ml were enrolled from June 2014 to June 2018. Demographic information and clinical data of liver function and HBV DNA load during gravidity, intrapartum and postpartum period were collected. According to the antiviral treatment recommendations during pregnancy, the women were divided into three groups, namely, tenofovir (TDF), telbivudine (LdT) and control group. Liver function abnormalities among the three groups were compared within 6 months after delivery, and the factors influencing abnormal liver function were analyzed by unconditional logistic regression.
Results:Of the 188 cases, 72 cases were in the TDF group, 80 cases in the LdT group, and 36 cases in the control group. Pregnant women in the TDF and LdT groups received oral TDF (300 mg/d) and LdT (600 mg/d) from 28 ± 4 weeks of gestation till delivery. Among the 188 patients, 30 (16.0%) had abnormal postpartum liver function abnormality. The incidence of postpartum liver function abnormality [alanine aminotransferase (ALT) > 2 × upper limit of normal (ULN)] in the TDF, LdT, and control groups was 19.4%, 12.5%, and 16.7%, respectively. The postpartum peak levels of ALT (median, range) in the three groups were 34.5 (12.0-946.0) U/L, 37.5 (12.0-733.8) U/L, and 39.0 (7.0-513.0) U/L, respectively. There was no significant difference between the two indexes among the three groups (P > 0.05). There was no statistically significant difference in the degree of postpartum liver function abnormalities between the three groups (P = 0.944). Most of the liver function abnormalities were mild to moderate (2 × ULN≤ALT < 10 × ULN), and usually resolved spontaneously or by treatment. Univariate and multivariate analysis showed that baseline ALT level during pregnancy was an independent factor associated with postpartum liver function abnormality (OR = 1.031, CI 95%: 1.005-1.058; χ2 = 5.340, P = 0.021), whereas age, antiviral therapy, HBeAg-positivity, baseline HBV DNA levels, gravidity, parity, preterm delivery and delivery mode were not significantly associated with postpartum liver function abnormality.
Conclusion:Cessation of antiviral therapy after delivery did not significantly increase the risk of postpartum liver function abnormality in pregnant women with chronic HBV infection. The ALT level during pregnancy is a factor influencing postpartum liver function abnormality.
